Elimination of breast tumor-associated chondroitin sulfate promotes metastasis

Genetics and Molecular Research

Volumn 10, Issue 4, 2011, Pages 3901-3913

  Prinz, R D ^c   Willis, C M ^a,c   Viloria Petit, A ^b   Kluppel M ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

^c CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

Author keywords

Breast cancer; Chondroitin sulfate; Chondroitinase ABC; Metastasis; Orthotopic tumor

Indexed keywords

CHONDROITIN ABC LYASE; CHONDROITIN SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN CARBOHYDRATE INTERACTION; SECOND CANCER; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; INJECTION; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROITIN ABC LYASE; CHONDROITIN SULFATES; FEMALE; INJECTIONS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE;

EID: 84861633686     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2011.December.8.9     Document Type: Article

References (46)

1. Alini M and Losa GA (1991). Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res. 51: 1443-1447.
2. Basappa MS, Sugahara KN, Lee CM, ten Dam GB, et al. (2009). Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology 19: 735-742.
3. Bradbury EJ and Carter LM (2011). Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. Brain Res. Bull. 84: 306-316.
4. Cafferty WBJ, Yang SH, Duffy PJ, Li S, et al. (2007). Functional axonal regeneration through astrocytic scar genetically modified to digest chondroitin sulfate proteoglycans. J. Neurosci. 27: 2176-2185.
5. Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, et al. (2011). Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 13: R58.
6. Coulson-Thomas YM, Coulson-Thomas VJ, Filippo TR, Mortara RA, et al. (2008). Adult bone marrow-derived mononuclear cells expressing chondroitinase AC transplanted into CNS injury sites promote local brain chondroitin sulphate degradation. J. Neurosci. Methods 171: 19-29.
7. Habuchi O (2000). Diversity and functions of glycosaminoglycan sulfotransferases. Biochim. Biophys. Acta 1474: 115-127.
8. Heinegard D (2009). Proteoglycans and more-from molecules to biology. Int. J. Exp. Pathol. 90: 575-586.
9. Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, et al. (2003). Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N. Y. Acad. Sci. 995: 151-161.
10. Hendrix MJ, Seftor EA, Seftor REB, Kasemeier-Kulesa J, et al. (2007). Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 7: 246-255.
11. Hochberg MC (2010). Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 18 (Suppl 1): S28-S31.
12. Hogan BV, Peter MB, Shenoy H, Horgan K, et al. (2010). Intramammary lymph node metastasis predicts poorer survival in breast cancer patients. Surg. Oncol. 19: 11-16.
13. Iida J, Wilhelmson KL, Ng J, Lee P, et al. (2007). Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem. J. 403: 553-563.
14. Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, et al. (2009). Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer: structural and expressional studies. Oncol. Rep. 22: 369-375.
15. Kawashima H, Hirose M, Hirose J, Nagakubo D, et al. (2000). Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J. Biol. Chem. 275: 35448-35456.
16. Kawashima H, Atarashi K, Hirose M, Hirose J, et al. (2002). Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4, 6-O-disulfate) interact with L-and P-selectin and chemokines. J. Biol. Chem. 277: 12921-12930.
17. Kenny PA, Lee GY and Bissell MJ (2007). Targeting the tumor microenvironment. Front Biosci. 12: 3468-3474.
18. Kim IS and Baek SH (2010). Mouse models for breast cancer metastasis. Biochem. Biophys. Res. Commun. 394: 443-447.
19. Klüppel M (2010). The roles of chondroitin-4-sulfotransferase-1 in development and disease. Prog. Mol. Biol. Transl. Sci. 93: 113-132.
20. Klüppel M (2011). Efficient secretion of biologically active Chondroitinase ABC from mammalian cells in the absence of an N-terminal signal peptide. Mol. Cell Biochem. 351: 1-11.
21. Klüppel M, Vallis KA and Wrana JL (2002). A high-throughput induction gene trap approach defines C4ST as a target of BMP signaling. Mech. Dev. 118: 77-89.
22. Klüppel M, Wight TN, Chan C, Hinek A, et al. (2005). Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development 132: 3989-4003.
23. Kovalszky I, Pogany G, Molnar G, Jeney A, et al. (1990). Altered glycosaminoglycan composition in reactive and neoplastic human liver. Biochem. Biophys. Res. Commun. 167: 883-890.
24. Krasnokutsky S, Samuels J and Abramson SB (2007). Osteoarthritis in 2007. Bull. NYU Hosp. Jt. Dis. 65: 222-228.
25. Kusche-Gullberg M and Kjellen L (2003). Sulfotransferases in glycosaminoglycan biosynthesis. Curr. Opin. Struct. Biol. 13: 605-611.
26. LaBarge MA, Petersen OW and Bissell MJ (2007). Of microenvironments and mammary stem cells. Stem. Cell Rev. 3: 137-146.
27. Li F, Ten Dam GB, Murugan S, Yamada S, et al. (2008). Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J. Biol. Chem. 283: 34294-34304.
28. Luo J, Kato M, Wang H, Bernfield M, et al. (2001). Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J. Cell Biochem. 80: 522-531.
29. Mego M, Mani SA and Cristofanilli M (2010). Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat. Rev. Clin. Oncol. 7: 693-701.
30. Monzavi-Karbassi B, Stanley JS, Hennings L, Jousheghany F, et al. (2007). Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int. J. Cancer 120: 1179-1191.
31. Mueller MM and Fusenig NE (2004). Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4: 839-849.
32. Olsen EB, Trier K, Eldov K and Ammitzboll T (1988). Glycosaminoglycans in human breast cancer. Acta Obstet. Gynecol. Scand. 67: 539-542.
33. Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, et al. (2006). Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J. Biochem. 140: 517-524.
34. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, et al. (1997). Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin. Cancer Res. 3: 983-992.
35. Ricciardelli C, Quinn DI, Raymond WA, McCaul K, et al. (1999). Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 59: 2324-2328.
36. Ricciardelli C, Sakko AJ, Stahl J, Tilley WD, et al. (2009). Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate 69: 761-769.
37. Sakko AJ, Butler MS, Byers S, Reinboth BJ, et al. (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol. Biomark. Prev. 17: 2488-2497.
38. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, et al. (2004). Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin. Cancer Res. 10: 2491-2498.
39. Teng YH, Tan PH, Chia SJ, Zam NA, et al. (2008). Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod. Pathol. 21: 893-901.
40. Thiele H, Sakano M, Kitagawa H, Sugahara K, et al. (2004). Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement. Proc. Natl. Acad. Sci. U. S. A. 101: 10155-10160.
41. Uebelhart D (2008). Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 16 (Suppl 3): S19-S21.
42. Vijayagopal P, Figueroa JE and Levine EA (1998). Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma. J. Surg. Oncol. 68: 250-254.
43. Viloria-Petit AM and Wrana JL (2010). The TGFbeta-Par6 polarity pathway: linking the Par complex to EMT and breast cancer progression. Cell Cycle 9: 623-624.
44. Viloria-Petit AM, David L, Jia JY, Erdemir T, et al. (2009). A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 106: 14028-14033.
45. Wandel S, Juni P, Tendal B, Nuesch E, et al. (2010). Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341: c4675.
46. Wegrowski Y and Maquart FX (2004). Involvement of stromal proteoglycans in tumour progression. Crit. Rev. Oncol. Hematol. 49: 259-268.